A fragment of something larger
BPC-157 is a partial sequence of body protection compound, a protein identified in human gastric juice. The synthetic fragment turned out to be stable in gastric conditions, which is unusual for a peptide and is part of why it drew attention.
The naming can mislead. BPC-157 is not the natural protein, it is a designed fragment, and results attributed to one should not be quietly transferred to the other.
You will also see the name written as a pentadecapeptide, which only restates the length, and sometimes followed by a salt form. That suffix describes the counter-ion the material was isolated with rather than a different sequence. It is not a detail to skim past: a document that names the peptide without naming the form it is supplied in has given you an incomplete identity statement.
A large animal literature, a missing human one
Published work spans tendon, ligament, muscle and gut injury models, mostly in rodents, and reports effects on healing markers with reasonable consistency across groups. There is more of it than the sceptics tend to acknowledge.
What is absent is the human half. Controlled human trials of any size have not been published, so the step from a rat tendon model to anything about a person is a step nobody has taken in print. That gap is the honest headline.
Anyone typing what is bpc-157 into a search engine will watch that gap get papered over almost immediately, usually with animal findings described in wording that quietly implies people. The indexed record on PubMed is the corrective. Note which model each paper used, one line per study, and the picture reassembles itself accurately.
| Length | 15 amino acids |
| Derived from | Body protection compound, gastric juice |
| Stability | Unusually stable in gastric conditions |
| Research focus | Tendon, ligament, muscle and gut injury models |
| Receptor | Not confirmed |
| Format | Peptide pen and capsules |
| Human trials | None published |
| Category | Research use only |
What the laboratory measured, and nothing beyond that.
Angiogenesis and the proposed route
The mechanism most often proposed involves promotion of new blood vessel formation and interaction with growth factor signalling, which would be a plausible route to the effects reported in the injury models.
Proposed is the operative word. No receptor has been confirmed, and a mechanism that fits the observations is not the same as a mechanism that has been demonstrated.
What would move the position is not another rodent study but a controlled trial in people, with a registered protocol and a result published either way. Until one exists the mechanism stays a hypothesis with observations behind it, which happens to be the fairest way to read the TB-500 file as well, the compound this one is most often paired with.
The BPC-157 capsule, the pen and the anti-doping line
Most peptides do not survive the gut, which is why the oral list in this catalogue is short. This one is among the exceptions, and its reported stability under gastric conditions is the only reason the capsule format exists for it at all. That is a statement about the chemistry of the molecule and not a claim about what an oral preparation achieves in any model, which remains a separate question.
Sport is the other practical constraint, and it is not a soft one. The compound is named on the prohibited list, and its forum reputation as something that will not show up is both beside the point and increasingly out of date. Our page on the list and peptides sets out how the categories are drawn; the list published by WADA is the instrument itself, and it is revised every January.
BPC-157 in the catalogue
Purity established at 99% minimum, documented against the lot number.
Where BPC-157 fits in
Reading that connects this page to the rest.
About BPC-157
The points that need clearing up most often.